Positron Emission Tomography Imaging of [11C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A

Using positron emission tomography imaging, we determined the hepatic concentrations and hepatobiliary transport of [11C]rosuvastatin (RSV; i.v. injection) in the absence (n = 6) and presence (n = 4 of 6) of cyclosporin A (CsA; i.v. infusion) following a therapeutic dose of unlabeled RSV (5 mg, p.o.) in healthy human volunteers. The sinusoidal uptake, sinusoidal efflux, and biliary efflux clearance (CL; mL/minute) of [11C]RSV, estimated through compartment modeling were 1,205.6 ± 384.8, 16.2 ± 11.2, and 5.1 ± 1.8, respectively (n = 6). CsA (blood concentration: 2.77 ± 0.24 μM), an organic‐anion‐transporting polypeptide, Na+‐taurocholate cotransporting polypeptide, and breast cancer resistance protein inhibitor increased [11C]RSV systemic blood exposure (45%; P < 0.05), reduced its biliary efflux CL (52%; P < 0.05) and hepatic uptake (25%; P > 0.05) but did not affect its distribution into the kidneys. CsA increased plasma concentrations of coproporphyrin I and III and total bilirubin by 297 ± 69%, 384 ± 102%, and 81 ± 39%, respectively (P < 0.05). These data can be used in the future to verify predictions of hepatic concentrations and hepatobiliary transport of RSV.

[1]  Paul D. Martin,et al.  A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. , 2003, Clinical therapeutics.

[2]  A. Reichel,et al.  Development of a fluorescence-based assay for drug interactions with human Multidrug Resistance Related Protein (MRP2; ABCC2) in MDCKII-MRP2 membrane vesicles. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[3]  S. L. Goss,et al.  Effect of Ritonavir on 99mTechnetium–Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIs , 2013, CPT: pharmacometrics & systems pharmacology.

[4]  Paul D. Martin,et al.  Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. , 2003, Clinical therapeutics.

[5]  Yi Wang,et al.  Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin , 2008, Drug Metabolism and Disposition.

[6]  Chi Heem Wong,et al.  Corrigendum: Estimation of clinical trial success rates and related parameters , 2018, Biostatistics.

[7]  W Bolch,et al.  ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances , 2015, Annals of the ICRP.

[8]  K. Krohn,et al.  Production of [11C]CH3I by single pass reaction of [11C]CH4 with I2. , 1997, Nuclear medicine and biology.

[9]  G. Szakács,et al.  Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography , 2017, Clinical pharmacology and therapeutics.

[10]  O. Nicolas,et al.  PBPK modeling of irbesartan: incorporation of hepatic uptake , 2015, Biopharmaceutics & drug disposition.

[11]  W. dodds,et al.  Effects of morphine on the human sphincter of Oddi. , 1988, Gut.

[12]  D. Mankoff,et al.  Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography , 2005, Clinical pharmacology and therapeutics.

[13]  Icrp.  ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances , 2015 .

[14]  N. Samani,et al.  Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction: The GEOSTAT-1 Study , 2010, Circulation. Cardiovascular genetics.

[15]  Christopher J. Endres,et al.  Interplay of drug metabolism and transport: a real phenomenon or an artifact of the site of measurement? , 2009, Molecular pharmaceutics.

[16]  A. Dane,et al.  The effect of fluconazole on the pharmacokinetics of rosuvastatin , 2002, European Journal of Clinical Pharmacology.

[17]  W. Humphreys,et al.  Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[18]  Hugh A. Barton,et al.  Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data , 2012, Drug Metabolism and Disposition.

[19]  Hirotaka Matsuo,et al.  Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations , 2016, Front. Pharmacol..

[20]  A. D. Rodrigues,et al.  Predicting Human Clearance of Organic Anion Transporting Polypeptide Substrates Using Cynomolgus Monkey: In Vitro–In Vivo Scaling of Hepatic Uptake Clearance , 2018, Drug Metabolism and Disposition.

[21]  Mark Muzi,et al.  Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using 11C-Verapamil in the Brain: Studies of Healthy Humans , 2009, Journal of Nuclear Medicine.

[22]  Jashvant D. Unadkat,et al.  Successful Prediction of In Vivo Hepatobiliary Clearances and Hepatic Concentrations of Rosuvastatin Using Sandwich-Cultured Rat Hepatocytes, Transporter-Expressing Cell Lines, and Quantitative Proteomics , 2018, Drug Metabolism and Disposition.

[23]  P. Neuvonen,et al.  Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2007, Clinical pharmacology and therapeutics.

[24]  Prajakti A Kothare,et al.  Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. , 2014, British journal of clinical pharmacology.

[25]  J. Unadkat,et al.  Transport vs. Metabolism: What Determines the Pharmacokinetics and Pharmacodynamics of Drugs? Insights From the Extended Clearance Model , 2016, Clinical pharmacology and therapeutics.

[26]  D. Mankoff,et al.  Regional P‐Glycoprotein Activity and Inhibition at the Human Blood–Brain Barrier as Imaged by Positron Emission Tomography , 2010, Clinical pharmacology and therapeutics.

[27]  Christopher J Endres,et al.  The role of transporters in drug interactions. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[28]  J. Polli,et al.  IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES , 2006, Drug Metabolism and Disposition.

[29]  K. Maeda,et al.  Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions , 2015, Drug Metabolism and Disposition.

[30]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[31]  R. Kim,et al.  Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. , 2006, Gastroenterology.

[32]  R. Venkataramanan,et al.  Blood Protein Binding of Cyclosporine in Transplant Patients , 1987, Journal of clinical pharmacology.

[33]  Nathan D. Pfeifer,et al.  Hepatic Basolateral Efflux Contributes Significantly to Rosuvastatin Disposition I: Characterization of Basolateral Versus Biliary Clearance Using a Novel Protocol in Sandwich-Cultured Hepatocytes , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[34]  W G SCHENK,et al.  Direct Measurement of Hepatic Blood Flow in Surgical Patients: With Related Observations on Hepatic Flow Dynamics in Experimental Animals , 1962, Annals of surgery.

[35]  R. Harrison,et al.  Phase II and phase III failures: 2013–2015 , 2016, Nature Reviews Drug Discovery.

[36]  K. Kanda,et al.  Total hepatocellular disposition profiling of rosuvastatin and pitavastatin in sandwich-cultured human hepatocytes. , 2018, Drug metabolism and pharmacokinetics.

[37]  W. Humphreys,et al.  Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[38]  Caroline A. Lee,et al.  Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment , 2005, Clinical pharmacology and therapeutics.

[39]  Y. Sugiyama,et al.  Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs , 2009, Expert opinion on drug metabolism & toxicology.

[40]  A. D. Rodrigues,et al.  Evaluation of Rosuvastatin as an Organic Anion Transporting Polypeptide (OATP) Probe Substrate: In Vitro Transport and In Vivo Disposition in Cynomolgus Monkeys , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[41]  Dylan Kissane.  The Rational Approach , 2012 .

[42]  Yuichi Sugiyama,et al.  Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium , 2018, Clinical pharmacology and therapeutics.

[43]  X. Chu,et al.  Evaluation of Cynomolgus Monkeys for the Identification of Endogenous Biomarkers for Hepatic Transporter Inhibition and as a Translatable Model to Predict Pharmacokinetic Interactions with Statins in Humans , 2015, Drug Metabolism and Disposition.

[44]  J. Brockmöller,et al.  Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. , 2013, Biochemical pharmacology.

[45]  B. Stieger,et al.  Imaging techniques to study drug transporter function in vivo. , 2018, Pharmacology & therapeutics.

[46]  J. Link,et al.  PET imaging of Oatp-mediated hepatobiliary transport of [(11)C] rosuvastatin in the rat. , 2014, Molecular pharmaceutics.

[47]  Yuichi Sugiyama,et al.  Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches , 2018, Clinical pharmacology and therapeutics.

[48]  G. T. Krishnamurthy,et al.  Cholecystokinin and morphine pharmacological intervention during 99mTc-HIDA cholescintigraphy: a rational approach. , 1996, Seminars in nuclear medicine.

[49]  Paul D. Martin,et al.  Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. , 2003, Clinical therapeutics.

[50]  W. Humphreys,et al.  Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects , 2017, Drug Metabolism and Disposition.

[51]  Yusong Chen,et al.  Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States , 2015, European Journal of Clinical Pharmacology.

[52]  M. D. de Broe,et al.  Human Proximal Tubular Epithelium Actively Secretes but Does Not Retain Rosuvastatin , 2008, Molecular Pharmacology.